Research ArticleTheranostics
The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer
Ali Afshar-Oromieh, Lars Peter Sattler, Walter Mier, Boris A. Hadaschik, Jürgen Debus, Tim Holland-Letz, Klaus Kopka and Uwe Haberkorn
Journal of Nuclear Medicine May 2017, 58 (5) 750-755; DOI: https://doi.org/10.2967/jnumed.116.183483
Ali Afshar-Oromieh
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
Lars Peter Sattler
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
Walter Mier
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
Boris A. Hadaschik
3Department of Urology, Heidelberg University Hospital, Heidelberg, Germany
Jürgen Debus
4Department of Radiation Oncology and Therapy, Heidelberg University Hospital, Heidelberg, Germany
Tim Holland-Letz
5Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany; and
Klaus Kopka
6Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
Uwe Haberkorn
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 5
May 1, 2017
The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer
Ali Afshar-Oromieh, Lars Peter Sattler, Walter Mier, Boris A. Hadaschik, Jürgen Debus, Tim Holland-Letz, Klaus Kopka, Uwe Haberkorn
Journal of Nuclear Medicine May 2017, 58 (5) 750-755; DOI: 10.2967/jnumed.116.183483
The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer
Ali Afshar-Oromieh, Lars Peter Sattler, Walter Mier, Boris A. Hadaschik, Jürgen Debus, Tim Holland-Letz, Klaus Kopka, Uwe Haberkorn
Journal of Nuclear Medicine May 2017, 58 (5) 750-755; DOI: 10.2967/jnumed.116.183483
Jump to section
Related Articles
Cited By...
- 61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging
- 61Cu-Labeled Radiotracers: Alternative or Choice?
- Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT
- Combination of Forced Diuresis with Additional Late Imaging in 68Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake
- Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity
- Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer
- Comparison of 3 Interpretation Criteria for 68Ga-PSMA11 PET Based on Inter- and Intrareader Agreement
- An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application
- Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging
- Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis
- Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology
- Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET
- Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment
- 18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution
- PSMA Ligands for PET Imaging of Prostate Cancer